CLINICAL RESEARCH

Impaired oxidation of debrisoquine in patients with perhexiline neuropathy

R R SHAH, N S OATES, J R IDLE, R L SMITH, J D F LOCKHART

Abstract

The use of perhexiline maleate as an antianginal agent is occasionally associated with side effects, particularly neuropathy and liver damage. The reason why some individuals develop these toxic reactions is not clear, though some evidence suggests that they may result from impaired oxidative metabolism, due to genetic or hepatic factors, and consequential accumulation of the drug in toxic concentrations. Drug oxidation was measured with an oxidation phenotyping procedure in 34 patients treated with perhexiline, 20 of whom had developed neuropathy and 14 of whom had not. Most of the 20 patients with neuropathy, but not the unaffected patients, showed an impaired ability to effect metabolic drug oxidation. This impairment was independent of hepatic function, concurrent drug therapy, or tobacco or alcohol consumption.

The fact that the ability to oxidise several drugs is genetically controlled points to a genetic susceptibility to developing neuropathy in response to perhexiline. Routine determination of the drug oxidation phenotype might lead to safer use of perhexiline by predicting patients who may be more at risk of developing a neuro-pathic reaction associated with its long-term use.

Introduction

Perhexiline maleate (Pexid), a synthetic antianginal agent, was first marketed in the UK in 1975. Clinical trials have shown its

efficacy in reducing both anginal attacks and the consumption of glyceryl trinitrate in patients with myocardial ischaemia.¹⁻³ Its mode of action is not fully understood, but it reduces exercise-induced tachycardia and improves exercise tolerance without effect on blood pressure or resting heart rate.⁴⁻⁵ It has calcium antagonistic properties⁶ and may exert some intracellular biochemical effect to reduce high-peak demand for oxygen during exercise or stress.⁷

The use of perhexiline has, however, become increasingly associated with adverse effects, both minor and major. The minor side effects, which include nausea, vomiting, dizziness, lethargy, insomnia, tremor, and loss of libido,⁸⁻¹¹ have not been too troublesome, and if they do not disappear spontaneously,⁹⁻¹¹ they can easily be controlled by reducing the dose or stopping the drug.⁸⁻⁹ The major side effects comprise peripheral neuropathy¹²⁻¹³; hepatic damage,¹⁴⁻¹⁵ including cirrhosis¹⁶; hypoglycaemia¹⁷; and weight loss.⁸⁻⁹ Proximal myopathy¹⁸ and papilloedema¹⁹⁻²⁰ have also been reported. Most of these effects are reversed when the drug is withdrawn, but the return of neurological and hepatic functions to normal may be slow or incomplete.

The reason why some people develop serious toxic reactions to perhexiline is not clear, though some evidence suggests that the reactions may result from impaired metabolism of the drug. Perhexiline is a lipophilic drug and its elimination depends on metabolic oxidation to the more polar monohydroxylated and dihydroxylated metabolites. The large interindividual variations in plasma half lives of perhexiline have been interpreted as being due to interindividual differences in the rate of metabolism of the drug.²¹ L'Hermitte *et al* suggested that perhexiline-induced neuropathy might represent individual susceptibility, perhaps secondary to some latent inborn metabolic disorder,²² and Singlas *et al* later showed that patients with peripheral neuropathy had higher perhexiline plasma concentrations and longer plasma half lives than those without peripheral neuropathy.²³ Furthermore, the mean ratio of plasma concentrations of the parent drug to those of its major metabolite, monohydroxy-perhexiline, was some nine times higher in the patients with neuropathy than in the controls, and they concluded that this toxic effect of perhexiline was associated with accumulation of the parent drug due to different patterns of distribution or metabolism in affected individuals.²³ The metabolic differences, in turn, were attributed

Department of Biochemical and Experimental Pharmacology,
St Mary's Hospital Medical School, London W2 1PG

R R SHAH, BSC, MRCP, Wellcome clinical research fellow

N S OATES, PHD, Wellcome research fellow

J R IDLE, PHD, lecturer in biochemical pharmacology

R L SMITH, DSC, PHD, professor of biochemical pharmacology

Merrell Pharmaceuticals Limited, Hounslow, Middlesex TW5 9QY

J D F LOCKHART, MB, DPH, director of clinical studies

to either genetic factors or the hepatic damage that may be associated with perhexiline therapy.²³

Recently it has been shown that several drug oxidations in man are under single gene control and exhibit genetic polymorphism.²⁴⁻²⁵ The genetic structure of a population with respect to oxidation is readily ascertained by the use of the drug debrisoquine, which is extensively oxidised by most individuals

(extensive metaboliser phenotype) to its major metabolite, 4-hydroxy-debrisoquine. About 9% of white British subjects, however, show impaired oxidation of debrisoquine (poor metaboliser phenotype).²⁴⁻²⁶ The oxidation is regulated by two alleles which have been referred to as the D^H (rapid and extensive oxidation) and the D^L alleles (slow impaired oxidation).²⁵ Individuals homozygous for the D^L allele have an impaired

TABLE 1—Details and results of the two groups of patients who received long-term perhexiline and those who never received perhexiline

Case No	Details				Liver function tests†							Approximate weekly consumption of perhexiline (g/week)
	Age and sex	Weight (kg)	Daily smoking*	Alcohol consumption	Bilirubin (μmol/l) (5-17)	AST (U/l) (7-40)	Alkaline phosphatase (U/l) (30-115)	Albumin (g/l) (35-51)	Globulin (g/l) (25-45)	ALT (U/l) (7-40)	Debrisoquine metabolic ratio	
Patients treated with perhexiline												
Neuropathic patients												
1	57 F	70	0	0	5	—	78	35	31	43	0.5	3.0
2	52 M	75	10 c	+	7	—	86	40	32	18	0.8	2.8
3	62 M	54	1 cg	0	6	—	72	39	33	12	0.9	1.3
4	58 M	57	1 cg	±	8	—	113	41	26	18	1.6	2.2
5	68 M	80	8 c	+	11	31	69	43	31	—	2.6	2.2
6	54 M	65	0	±	10	67	234	24	43	—	2.6	2.1
7	62 M	72	0	±	<17	55	25	40	25	—	4.5	2.1
8	55 M	76	40 c	0	<17	<40	<115	>35	<45	—	5.7	2.1
9	68 M	73	Pipe	±	12	23	54	40	32	—	8.5	2.1
10	69 M	89	Pipe	0	8	45	9	38	31	62	10	2.4
11	60 M	76	0	0	8	46	112	45	27	—	19	2.0
12	73 F	45	0	0	4	106	67	32	28	—	25	1.4
13	60 M	79	0	±	8	123	10	40	32	176	27	2.3
14	56 M	86	0	±	14	18	160	51	20	—	28	2.0
15	66 M	77	Pipe	±	<17	34	<115	>35	<45	61	30	1.4
16	63 M	68	0	±	6	—	85	29	31	16	32	1.4
17	68 M	62	0	±	11	152	110	36	34	—	35	1.8
18	68 M	65	6 c	±	8	15	50	>35	<45	—	69	1.4
19	60 M	76	0	±	<17	<40	<115	>35	<45	—	77	1.4
20	67 M	76	5 c	±	9	25	94	47	25	—	>100	2.3
Mean	62.3	71.1			10.2	54.7	88.8	38	33.1			1.99
±SD	±5.8	±10.7			±4.2	±40.8	±51.5	±6.1	±7.6			±0.48
Non-neuropathic patients												
21	66 M	70	0	+	4	33	110	43	29	—	0.4	3.1
22	57 M	78	0	±	<17	23	23	29	34	—	0.4	3.8
23	76 F	57	0	0	12	17	92	42	29	11	0.5	1.4
24	55 M	69	Pipe	±	17	<40	<115	>35	<45	—	0.5	1.5
25	62 M	58	0	0	9	64	87	39	29	—	0.6	2.1
26	50 M	91	0	±	6	36	57	44	28	—	0.6	2.1
27	67 M	75	6 c	±	11	23	79	40	24	22	0.6	2.1
28	58 M	65	0	±	3	15	191	44	23	—	0.7	3.7
29	71 M	74	0	±	9	23	85	43	32	—	1.0	2.1
30	71 F	53	0	±	14	28	92	41	27	—	1.1	2.1
31	74 M	71	0	0	12	21	110	42	32	—	1.1	2.8
32	71 F	57	0	0	7	—	74	38	30	21	1.6	1.4
33	60 M	52	0	0	<10	16	25	41	27	—	1.7	3.8
34	73 F	67	0	+	8	112	93	40	26	—	4.6	1.4
Mean	65.1	66.9			9.9	34.7	88.1	40.1	29.6			2.39
±SD	±8.1	±10.9			±4.3	±26.7	±41	±4.0	±5.4			±0.90
Patients who never received perhexiline												
35	68 M	67	0	±	15	105	74	45	28	—	0.1	
36	58 M	107	0	±	7	22	42	44	23	—	0.1	
37	74 M	71	0	0	9	26	140	42	27	—	0.1	
38	70 M	65	0	0	8	19	102	45	29	—	0.2	
39	59 M	89	0	+	8	77	297	41	27	—	0.2	
40	59 M	92	5 c	±	5	20	100	43	25	—	0.2	
41	53 M	76	2 cg	+	12	27	221	42	37	—	0.2	
42	58 M	69	0	±	7	20	58	41	23	—	0.2	
43	39 M	83	0	+	7	36	101	48	26	—	0.2	
44	54 M	61	0	±	7	26	110	42	29	—	0.3	
45	60 M	68	0	+	14	36	78	43	23	—	0.3	
46	71 M	60	7 c	±	8	29	98	41	24	—	0.3	
47	48 M	80	0	0	7	29	108	45	23	—	0.3	
48	68 F	47	0	±	7	20	112	46	30	—	0.4	
49	50 M	86	0	+	9	32	99	49	24	—	0.4	
50	51 M	54	6 c	0	4	23	98	40	20	—	0.5	
51	77 M	65	0	0	5	25	111	39	26	—	0.5	
52	38 M	76	0	±	4	26	57	44	32	—	0.5	
53	71 M	81	10 c	±	8	19	92	41	28	—	0.5	
54	32 M	69	0	±	9	25	83	48	18	—	0.6	
55	45 M	73	0	±	7	22	95	44	24	—	0.6	
56	41 M	86	15 c	0	4	23	140	45	29	—	0.6	
57	46 M	65	0	0	15	32	95	48	34	—	0.7	
58	53 M	69	1 cg	±	9	32	56	43	23	—	1.0	
59	79 M	52	0	±	6	22	151	46	31	—	1.0	
60	51 M	83	3 c	0	3	32	104	44	27	—	1.1	
61	66 M	67	0	+	7	21	82	43	18	—	1.4	
62	55 M	82	0	±	11	45	101	45	27	—	1.7	
63	69 M	87	14 c	±	5	28	139	44	29	—	1.9	
64	70 M	69	0	0	7	33	114	43	25	—	2.3	
65	67 M	57	15 c	±	5	21	126	41	33	—	2.6	
66	47 M	83	0	±	3	15	76	46	26	—	2.8	
67	62 M	73	15 c	+	6	19	89	45	29	—	4.0	
68	52 F	71	10 c	±	5	22	78	44	26	—	4.5	
69	70 F	55	0	±	3	21	130	44	26	—	5.6	
70	62 M	74	5 c	±	7	38	65	44	28	—	15	
71	59 M	67	0	±	13	27	97	41	24	—	26	
72	59 M	80	0	±	5	19	74	40	23	—	39	
Mean	58.2	72.6			7.4	29.3	102	43.7	26.4			
±SD	±11.5	±12.3			±3.2	±16.4	±47.7	±2.4	±4.0			

*c=cigarette; cg=cigar; 0=none; ±=only occasionally; +=mild to moderate; -=not determined. †Normal reference range in parentheses. AST=Aspartate aminotransferase. ALT=Alanine aminotransferase. Conversion: SI to traditional units—Bilirubin: 1 μmol/l ≈ 0.06 mg/100 ml.

ability to oxidise several other drugs besides debrisoquine.^{25 27 28} This genetic polymorphism in drug oxidation reactions has several important implications. One of the more significant is that in subjects with impairment drugs that are normally eliminated by oxidation are more likely to accumulate, possibly to toxic concentrations.²⁹

We therefore investigated patients who had developed perhexiline-induced neuropathy for their debrisoquine oxidation status on the supposition that the toxicity could be the result of an impaired ability to eliminate drugs through oxidation.

Patients and methods

Twenty patients with past or present perhexiline-induced neuropathy confirmed by nerve conduction studies (18) or definite clinical evidence (2), were identified from various cardiac outpatient departments. Another 14 patients who received perhexiline for angina and who had had no serious side effects on long term treatment served as controls. A further 38 patients with ischaemic heart disease who had never had perhexiline were also included in the study to assess the influence of the disease on oxidation pattern and also to determine whether the disease had predilection for any particular oxidation status. Approval was obtained from the St Mary's Hospital ethical committee, and each patient gave his or her informed consent before participating in the study. The details of these patients and, where appropriate, the approximate weekly intake of perhexiline are given in table I.

All the patients were phenotyped for oxidation status,²⁴ and each took a single 10-mg oral dose of debrisoquine (Declinax 10, Roche). The urine passed in the subsequent eight hours was collected in bulk, the volume measured, and a 20-ml sample stored at -20°C before analysis. Each sample was analysed for its content of parent drug and its major metabolite, 4-hydroxy-debrisoquine using electron-capture gas chromatography. From the results, the metabolic ratio was calculated. This ratio defines an individual's ability to metabolise debrisoquine (and by inference several other drugs) and is derived as follows:

$$\frac{\% \text{ dose excreted as unchanged debrisoquine}}{\% \text{ dose excreted as 4-hydroxy-debrisoquine}} \text{ in the 0-8 h urine}$$

after a single 10-mg oral dose of the drug. Low values (<1) represent extensive oxidative ability, while values greater than 12.6 indicate the grossly impaired ability found in the individuals homozygous for the D¹ allele.²⁶ Intermediate ratios indicate varying degrees of impairment.

To assess their hepatic function, routine biochemical liver function tests were carried out on all the patients included in this study. Most of these tests were performed within one week of the debrisoquine phenotyping test.

Results

Table I shows the details of the 34 patients who received long-term perhexiline treatment for angina, together with the results of their liver function tests and their debrisoquine metabolic ratios. The 20 patients who developed neuropathy consisted of 18 men and 2 women while the 14 patients who did not develop this complication included 10 men and 4 women. There were no significant differences between the two groups in terms of their age, weight, or alcohol consumption. Ten of the 20 neuropathic patients and two of the 14 non-neuropathic individuals consumed tobacco in some form. Both groups were exposed to comparable dosages of perhexiline. In the eight hours the mean ($\pm$ SD) urinary recoveries of debrisoquine plus 4-hydroxy-debrisoquine were $29.8 \pm 13.1\%$ (range 14-67%) in the neuropathic group and $26.1 \pm 10.7\%$ (range 12-53%) in the non-neuropathic group. The patients fell into two fairly well defined groups with respect to their oxidation status and the development of neuropathy.

The patients who developed neuropathy showed metabolic ratios in the range 0.5- >100 with a median value of 14.4 whereas the range for the non-neuropathic group was 0.4-4.6 with a median value of 0.65. The median metabolic ratio of the neuropathic group was significantly greater than that of the non-neuropathic group as determined by the Wilcoxon rank test. There were many more patients with ratios of more than 12.6 (50%) and fewer with ratios of less than 1.0 (15%) among those who developed neuropathy. This preponderance of individuals with high metabolic ratios was significantly greater ($\chi^2 =$

37.9; $p < 0.0001$) in the neuropathy group than would have been expected in normal healthy population^{24 26} or in a random sample of patients with ischaemic heart disease (see below). Correspondingly, the neuropathy group contained significantly fewer ($\chi^2 = 7.6$, $p < 0.01$) individuals with metabolic ratios of less than 1.0.

Table I also shows details of the 38 patients (35 men and 3 women) with ischaemic heart disease who were not prescribed perhexiline and the results of their liver function tests and debrisoquine metabolic ratios. This group of patients did not differ in age, weight, alcohol or tobacco consumption, or biochemical liver function values from the two perhexiline-treated groups. Their mean eight-hour urinary recovery of debrisoquine plus 4-hydroxy-debrisoquine ($33.9 \pm 9.3\%$, range 11-62%) was also comparable. These patients had metabolic ratios of 0.1-39 with a median value of 0.55. Only three patients had a ratio greater than 12.6 (8%), whereas 25 had a ratio of less than 1.0 (66%). The remaining 10 patients (26%) had intermediate ratios.

Discussion

The question arises whether the metabolic impairment in the neuropathic patients was due to hepatic dysfunction produced by perhexiline treatment. It is impossible to generalise about the effect of liver dysfunction on drug oxidation since the findings are inconsistent and sometimes contradictory.³⁰ Thus, the rate of metabolism of phenylbutazone,³¹ aminopyrine,³² bishydroxycoumarin,³² antipyrine,³³ tolbutamide,³³ and pentobarbital³⁴ were not significantly changed, while other investigations have shown the half lives of phenylbutazone³⁵ and meprobamate³⁶ to be prolonged in patients with liver dysfunction. A leading article in the *Lancet*³⁷ concluded that even patients with advanced chronic liver disease metabolise drugs surprisingly normally. There was no significant difference between our three groups in their various liver function values. In the 72 patients investigated there was no correlation between the measured metabolic ratios and any of the liver function values. Therefore the difference in debrisoquine metabolic ratios between the two perhexiline-treated groups of patients probably did not originate in hepatic dysfunction. Furthermore, we have found in unpublished studies that the metabolic ratio for debrisoquine is unaffected by mild-to-moderate hepatic damage unless accompanied by hyperbilirubinaemia. Similarly, no difference was discernible between the two groups of patients on perhexiline in terms of their smoking habits or alcohol consumption.

All except four of the perhexiline-treated patients had discontinued perhexiline at least four weeks before being phenotyped. The concurrent drug treatment of all the patients studied at the time of the assessment of their oxidation status is shown in table II. It may be suggested that certain drugs when taken concurrently may influence each other's metabolic fate and therefore that the metabolic ratios of patients with neuropathy may be artefactually raised. Evidence against this suggestion is provided by our group of 38 patients with ischaemic heart disease. The pattern of drug treatment in this group was similar to that in the two perhexiline-treated groups (table II); they had metabolic ratios in the range of 0.1-39 and a median metabolic ratio of 0.55, which was lower than that of normal healthy population (0.8) receiving no medication. The proportion of individuals with metabolic ratios greater than 12.6 (7.9%) among these 38 patients was also close to that in healthy population.²⁶ Therefore the reason for the pronounced differences in the distribution of the metabolic ratios between the neuropathy group compared and the other two groups was not the result of concurrent drug treatment.

These results show a clear association between the occurrence of perhexiline-induced neuropathy and diminished drug metabolic ability as shown by debrisoquine hydroxylation. They suggest that individuals of poor metaboliser phenotype are at greater risk of developing neuropathy from long-term perhexiline therapy. This risk is strikingly reduced in extensive metabolisers who have metabolic ratios of less than 1.

The association between diminished drug oxidation status and propensity to develop a neuropathic reaction to perhexiline

makes it plausible to suggest that perhexiline would tend to accumulate in individuals with impaired drug oxidising ability because of defective metabolic elimination. The accumulation of the parent drug may then produce toxic sequelae. The mechanism of these toxic reactions is unknown, but drug-induced disturbances of lipid metabolism have been implicated.³⁸

Without any obvious causes three of our 20 patients developed neuropathy despite their metabolic ratios being less than 1. It therefore seems likely that, although an individual's drug oxidation status may be a major pharmacokinetic determinant of drug response (toxic or therapeutic), other, as yet unidentified, factors may also contribute to producing toxic sequelae in a few patients. Such factors may include disorders affecting the

TABLE II—Details of concurrent drug therapy in 34 perhexiline-treated patients at the time of phenotyping and in 38 patients who had never received perhexiline

Case No (metabolic ratio)	Drugs
<i>Patients treated with perhexiline</i>	
Neuropathic patients	
1 (0.5)	Frusemide, nitrates, potassium supplements
2 (0.8)	Propranolol, nifedipine
3 (0.9)	Propranolol, nifedipine, digoxin
4 (1.6)	Metoprolol, frusemide, potassium supplements
5 (2.6)	Nitrates
6 (2.6)	Warfarin, salbutamol, thiazide, spironolactone
7 (4.5)	Nifedipine
8 (5.7)	Atenolol, nifedipine, nitrates, warfarin, dipyridamole
9 (8.5)	Propranolol
10 (10)	Oxprenolol, thiazide, potassium supplements
11 (19)	Atenolol, perhexiline, nitrates
12 (25)	Propranolol
13 (27)	Acebutolol, thiazide, potassium supplements
14 (28)	None
15 (30)	Oxprenolol, metformin, chlorpropamide
16 (32)	Metoprolol, thiazide, amiloride
17 (35)	Oxprenolol, perhexiline
18 (69)	Metoprolol
19 (77)	Propranolol, nifedipine, thiazide, amiloride
20 (>100)	Dipyridamole, theophylline, chlorthalidone, cinnarizine
Non-neuropathic patients	
21 (0.4)	None
22 (0.4)	Nitrates, frusemide, spironolactone
23 (0.5)	Atenolol, nifedipine, frusemide, potassium supplements
24 (0.5)	Aspirin, allopurinol, dipyridamole
25 (0.6)	Digoxin, perhexiline, nitrates, thiazide, potassium supplements
26 (0.6)	Metoprolol, nitrates, triamterene
27 (0.6)	Nitrates
28 (0.7)	Bumetanide, potassium supplements, phenytoin, phenobarbitone, salbutamol, naproxen
29 (1.0)	Propranolol, thiazide, potassium supplements
30 (1.1)	Propranolol, nitrates, thiazide, potassium supplements
31 (1.1)	Propranolol, nifedipine, allopurinol
32 (1.6)	Triamterene, oxazepam
33 (1.7)	Perhexiline
34 (4.6)	Metoprolol, perhexiline, nitrates
<i>Patients who never received perhexiline</i>	
35 (0.1)	Nitrates, thiazide, frusemide, potassium supplements
36 (0.1)	Thyroxine, dipyridamole
37 (0.1)	None
38 (0.2)	Nitrates, thiazide, potassium supplements
39 (0.2)	Digoxin, metoprolol, warfarin
40 (0.2)	None
41 (0.2)	Digoxin, frusemide, spironolactone, tetracycline
42 (0.2)	None
43 (0.2)	None
44 (0.3)	Digoxin, labetalol, thiazide, amiloride
45 (0.3)	Digoxin
46 (0.3)	Propranolol, thiazide, potassium supplements
47 (0.3)	Metoprolol, nitrates, warfarin
48 (0.4)	Metoprolol
49 (0.4)	Digoxin, frusemide, spironolactone, prazosin
50 (0.5)	None
51 (0.5)	Digoxin, metoprolol, nitrates, frusemide, metformin, chlorpropamide, potassium supplements
52 (0.5)	Propranolol
53 (0.5)	Metoprolol, nitrates
54 (0.6)	Propranolol
55 (0.6)	Warfarin
56 (0.6)	Propranolol
57 (0.7)	Digoxin, nitrates, bumetanide, potassium supplement, clofibrate
58 (1.0)	Nitrates
59 (1.0)	Digoxin, metoprolol, nitrates, bumetanide, potassium supplements
60 (1.1)	Digoxin, propranolol, nitrates, thiazide, amiloride, warfarin
61 (1.4)	Metoprolol, nitrates, amiloride
62 (1.7)	None
63 (1.9)	Nifedipine, thiazide
64 (2.3)	Digoxin, nitrates, thiazide, frusemide, amiloride, potassium supplements
65 (2.6)	Digoxin, nitrates, thiazide
66 (2.8)	Propranolol, nitrates, frusemide, dipyridamole, potassium supplements
67 (4.0)	None
68 (4.5)	Labetalol
69 (5.6)	Propranolol
70 (15)	Atenolol, nitrates, chlorthalidone
71 (26)	None
72 (39)	Propranolol, prenylamine, thioridazine

immune system or lipid metabolism and pharmacodynamic sensitivity.

These findings suggest that routine determination of oxidation status using debrisoquine could be of predictive value in determining perhexiline dosage and controlling its neurotoxicity. Significant associations have already been shown between impaired debrisoquine oxidation and susceptibility to debrisoquine-induced postural hypotension³⁹; phenacetin-induced methaemoglobinemia²⁹; phenformin-induced changes in blood lactic acid concentrations^{40, 41}; and nortriptyline-induced vertigo, dizziness, and confusional state.⁴² Bertilsson *et al* found that nortriptyline could be reintroduced successfully at much lower doses in patients with high debrisoquine metabolic ratios.⁴² Our findings suggest that, similarly, perhexiline can be used successfully in the treatment of angina pectoris without any appreciable danger of precipitating peripheral neuropathy provided the dose is tailored to the patient's oxidation status.

We thank the Wellcome Trust for their financial support of this project and to all the physicians who allowed us to study their patients. We also acknowledge the patients' co-operation.

References

- Armstrong ML. A comparative study of perhexiline, beta-adrenergic blocking agents and placebos in the management of angina pectoris. *Postgrad Med J* 1973;**49**, suppl 3:108-11.
- Dettori AG, Malagnino G, Fatt F, Oriani G. Perhexiline versus prenylamine. A controlled clinical trial in coronary insufficiency. *Postgrad Med J* 1973;**49**, suppl 3:113-4.
- Cawein MJ, Lewis RE, Hudak WJ, Hoekenga MT. Clinical evaluation of perhexiline maleate in patients with angina pectoris associated with a positive coronary artery disease index. *Postgrad Med J* 1973;**49**, suppl 3:121-4.
- Morledge J. Effects of perhexiline maleate in angina pectoris: double-blind clinical evaluation with ECG-treadmill exercise testing. *Postgrad Med J* 1973;**49**, suppl 3:64-7.
- Sukerman M. Clinical evaluation of perhexiline maleate in the treatment of chronic cardiac arrhythmias of patients with coronary artery disease. *Postgrad Med J* 1973;**49**, suppl 3:46-52.
- Fleckenstein-Grün G, Fleckenstein A, Byon YK, Kim KW. Mechanisms of action of calcium antagonists in the treatment of coronary disease with special reference to perhexiline maleate. In: *International symposium on perhexiline maleate*. Amsterdam: Excerpta Medica, 1978:1-22. (Excerpta Medica International Congress series No 424).
- Pepine CJ, Schang SJ, Bemiller CR. Alteration of left ventricular responses to ischaemia with oral perhexiline. *Postgrad Med J* 1973;**49**, suppl 3:43-6.
- Pilcher J, Chandrasekhar KP, Russell RJ, Boyce MJ, Peirce TH, Ikram H. Long-term assessment of perhexiline maleate in angina pectoris. *Postgrad Med J* 1973;**49**, suppl 3:115-8.
- Gitlin N, Nellen M. Perhexiline maleate in the treatment of angina pectoris: a double-blind trial. *Postgrad Med J* 1973;**49**, suppl 3:100-4.
- Gitlin N. Perhexiline maleate in the management of patients with angina pectoris. *S Afr Med J* 1974;**48**:904-6.
- Datey KK, Bagri AK, Kelkar PN, Varma SR, Bhootra RK, Amin BM. Perhexiline maleate: a new antianginal drug. *Postgrad Med J* 1973;**49**, suppl 3:75-8.
- Abaza A, Cattani D, Aziza C, Pappo E. Effets de secondaires mais réversibles à la prise de perhexiline. *Nouv Presse Med* 1973;**2**:2820.
- Laplane D, Bousser MG, Bouche P, Touboul PJ. Peripheral neuropathies caused by perhexiline maleate. In: *International symposium on perhexiline maleate*. Amsterdam: Excerpta Medica, 1978:89-96. (Excerpta Medica International Congress series No 424).
- Newberne JW. Assessment of safety data from patients on short- and long-term perhexiline therapy. *Postgrad Med J* 1973;**49**, suppl 3:125-9.
- Lewis D, Wainwright HC, Kew MC, Zwi S, Isaacson C. Liver damage associated with perhexiline maleate. *Gut* 1979;**20**:186-9.
- Pessayre D, Bichara M, Feldmann G, Degott C, Potet F, Benhamou J. Perhexiline maleate-induced cirrhosis. *Gastroenterology* 1979;**76**:170-7.
- Houdet CE, Wolf LM, Corriat A. Liver during perhexiline hypoglycaemia. *Lancet* 1977;ii:1028.
- Tomlinson IW, Rosenthal FD. Proximal myopathy after perhexiline maleate treatment. *Br Med J* 1977;ii:1319-20.
- Hutchinson WM, Williams J, Cawler J. Papilloedema in patients taking perhexiline maleate. *Br Med J* 1978;ii:305.
- Atkinson AB, McAreavey D, Trope G. Papilloedema and hepatic dysfunction apparently induced by perhexiline maleate (Pexid). *Br Heart J* 1980;**43**:490-1.
- Wright GJ, Leeson GA, Zeiger AV, Lang JF. The absorption, excretion and metabolism of perhexiline maleate by the human. *Postgrad Med J* 1973;**49**, suppl 3:8-15.

- ²² L'Hermitte F, Fardeau M, Chedru F, Mallecourt J. Polyneuropathy after perhexiline maleate therapy. *Br Med J* 1976;ii:1256.
- ²³ Singlas E, Goujet MA, Simon P. Pharmacokinetics of perhexiline maleate in anginal patients with and without peripheral neuropathy. *Eur J Clin Pharmacol* 1978;14:195-201.
- ²⁴ Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. *Lancet* 1977;ii:584-6.
- ²⁵ Sloan TP, Mahgoub A, Lancaster R, Idle JR, Smith RL. Polymorphism of carbon oxidation of drugs and clinical implications. *Br Med J* 1978;ii:655-7.
- ²⁶ Price Evans DA, Mahgoub A, Sloan TP, Idle JR, Smith RL. A family and population study of the genetic polymorphism of debrisoquine oxidation in a British white population. *J Med Genet* 1980;17:102-5.
- ²⁷ Sloan TP, Idle JR, Smith RL. Influence of D^H/D^L alleles regulating debrisoquine oxidation on phenytoin hydroxylation. *Clin Pharmacol Ther* 1981;29:493-7.
- ²⁸ Shah RR, Oates NS, Idle JR, Smith RL. Genetic impairment of phenformin metabolism. *Lancet* 1980;ii:1147.
- ²⁹ Ritchie JC, Sloan TP, Idle JR, Smith RL. Toxicological implications of polymorphic drug metabolism. In: *Environmental chemicals, enzyme function and human disease*. (Ciba Foundation Symposium 76). Amsterdam; Excerpta Medica, 1980:219-44.
- ³⁰ Williams RL, Mamelok RD. Hepatic disease and drug pharmacokinetics. *Clin Pharmacokinet* 1980;5:528-47.
- ³¹ Weiner M, Chenkin T, Burns JJ. Observations on the metabolic transformation and effects of phenylbutazone in subjects with hepatic disease. *Am J Med Sci* 1954;228:36-9.
- ³² Brodie BB, Burns JJ, Weiner M. Metabolism of drugs in subjects with Laennec's cirrhosis. *Med Exp* 1959;1:290-2.
- ³³ Nelson E. Rate of metabolism of tolbutamide in test subjects with liver disease or with impaired renal function. *Am J Med Sci* 1964;248:657-9.
- ³⁴ Oldershausen HF von, Held H, Remmer H. Der Abbau von Pentobarbital bei Leberschaden. *Klin Wochenschr* 1970;48:565-7.
- ³⁵ Levi AJ, Sherlock S, Walker D. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. *Lancet* 1968;ii:1275-9.
- ³⁶ Held H, Oldershausen HF von. Zur Pharmakokinetik von Meprobamat bei chronischen Hepatopathien und Arzneimittelsucht. *Klin Wochenschr* 1969;47:78-80.
- ³⁷ Anonymous. Drug metabolism in disease. *Lancet* 1974;ii:790-1.
- ³⁸ Pollet S, Hauw JJ, Escourolle R, Baumann N. Peripheral-nerve lipid abnormalities in patients on perhexiline maleate. *Lancet* 1977;ii:1258.
- ³⁹ Idle JR, Mahgoub A, Lancaster R, Smith RL. Hypotensive response to debrisoquine and hydroxylation phenotype. *Life Sci* 1978;22:979-84.
- ⁴⁰ Idle JR, Oates NS, Shah RR, Smith RL. Is there a genetic predisposition to phenformin-induced lactic acidosis? *Br J Clin Pharmacol* 1981;11:418P-9P.
- ⁴¹ Oates NS, Shah RR, Idle JR, Smith RL. Phenformin-induced lactic acidosis associated with impaired debrisoquine hydroxylation. *Lancet* 1981;ii:837-8.
- ⁴² Bertilsson L, Mellström B, Sjöqvist F, Mårtensson B, Åsberg M. Slow hydroxylation of nortriptyline and concomitant poor debrisoquine hydroxylation: Clinical implications. *Lancet* 1981;ii:561-2.

(Accepted 6 October 1981)

Effects of alcohol and smoking on blood lead in middle-aged British men

A G SHAPER, S J POCOCK, MARY WALKER, C J WALE, BARBARA CLAYTON, H T DELVES, LESLEY HINKS

Abstract

A survey of middle-aged men in 24 British towns showed a strong association between blood lead concentrations, alcohol consumption, and cigarette smoking. The association with alcohol persisted after age, social class, body mass index, cigarette smoking, water lead concentrations, and the town of residence had been taken into account. There was an independent but less pronounced association between cigarette smoking and blood lead concentrations after adjustment for the other factors. The possible mechanisms include a decreased excretion of lead due to alcohol-induced hepatic dysfunction and an increased lead intake from cigarette smoking.

These findings have implications for widespread measurement of blood lead concentrations in adults in the community and for all studies attempting to relate blood lead concentrations to environmental exposure.

Department of Clinical Epidemiology and General Practice, Royal Free Hospital School of Medicine, London NW3 2QG

A G SHAPER, FRCP, FRCPATH, professor of clinical epidemiology

S J POCOCK, MSC, PHD, senior lecturer in medical statistics

MARY WALKER, SRN, SCM, research administrator

C J WALE, statistical technician

Department of Chemical Pathology and Human Metabolism, University of Southampton, Southampton SO9 4XY

BARBARA E CLAYTON, FRCP, FRCPATH, professor of chemical pathology and human metabolism

H T DELVES, PHD, FRSC, honorary senior lecturer in chemical pathology

LESLEY HINKS, FIMLS, senior medical laboratory scientific officer

Introduction

The British Regional Heart Study seeks to explain the substantial geographical variations in cardiovascular mortality in Great Britain by evaluating the role of environmental, socioeconomic, and personal risk factors. The role of water quality is of particular interest, and analysis of data collected in the study has recently shown that cardiovascular mortality is about 10% higher in areas with very soft water than in areas with medium-hard water, after appropriate adjustments have been made for other factors such as climate and socioeconomic circumstances.¹ The mechanism by which soft water is associated with a higher cardiovascular mortality is uncertain but one of the possibilities considered was the increased water lead concentrations seen in many soft, acid waters.²⁻³

The Regional Heart Study includes a clinical survey of middle-aged men in 24 British towns, carried out to determine the distribution of established or possible risk factors for cardiovascular disease, to examine their interrelationships and to initiate a long-term prospective study of cardiovascular disease based on these findings.⁴ The survey has included the measurement of blood lead concentrations, and this report describes some relationships observed between blood lead concentration, cigarette smoking, and alcohol consumption in these middle-aged men.

Subjects and methods

The British Regional Heart Study covers 7735 men aged 40-59 years randomly selected from the age-sex registers of representative general practices in 24 British towns. The criteria for selecting the towns, the general practices, and the subjects as well as the methods of data collection have been presented in a separate report.⁴ In brief,